Disease · MONDO_0004608
Trials58
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
1 to 20 of 58
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01302834 | Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer | Phase 3 | 987 | 2020-01-09 | Head and Neck Cancer, Precancerous Condition | CETUXIMAB, CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | Phase 2 | 519 | 2022-09-28 | Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx | CARBOPLATIN, CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | Phase 2/3 | 384 | 2025-05-02 | Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma | CISPLATIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02254278 | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | Phase 2 | 316 | 2020-08-12 | Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | Phase 1/2 | 224 | 2026-03-09 | Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01932697 | Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer | Phase 2 | 81 | 2019-09-18 | Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma | DOCETAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | Phase 2 | 62 | 2021-01-08 | Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx | CARBOPLATIN, CISPLATIN, FLUOROURACIL, HYDROXYUREA, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | Phase 2 | 57 | 2022-02-28 | Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vaginal or Penile Cancer | BINTRAFUSP ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Phase 1/2 | 51 | 2023-11-18 | Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | BINTRAFUSP ALFA, IMMUNOCYTOKINE NHS-IL12, PEXIPEPIMUT-S | Its record names the disease | ClinicalTrials.gov |
| NCT01663259 | Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients | Not applicable | 43 | 2020-10-26 | Squamous Cell Carcinoma of the Oropharynx, HPV | CETUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01687413 | Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer | Phase 3 | 42 | 2020-11-10 | Oropharyngeal Neoplasms | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02426892 | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | Phase 2 | 33 | 2023-04-18 | Solid Tumors | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01585428 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | Phase 2 | 29 | 2017-03-23 | Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01706939 | The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | Phase 3 | 23 | 2022-09-01 | Squamous Cell Carcinomas | CARBOPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Early phase 1 | 17 | 2025-03-17 | Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma | DURVALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | Phase 1/2 | 12 | 2017-08-02 | Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | Phase 1/2 | 11 | 2024-01-11 | Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | Phase 2 | 6 | 2023-03-08 | Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | METFORMIN HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04116047 | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) | Phase 3 | 785 | Oropharyngeal Cancer | CISPLATIN, DURVALUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03811015 | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | Phase 3 | 636 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | CISPLATIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004608/trials